位置:首页 > 产品库 > Cisplatin(CDDP)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cisplatin(CDDP)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cisplatin(CDDP)图片
CAS NO:15663-27-1
规格:≥98%
包装与价格:
包装价格(元)
100mg询价
250mg询价
500mg询价
1g询价
2g询价
5g询价

理化性质和储存条件
Molecular Weight (MW)300.05
FormulaCl2H6N2Pt
CAS No.15663-27-1
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO:>10 mL
Water: <1 mg/mL
Ethanol:<1 mg/mL (slightly soluble or insoluble)
Solubility (In vivo)Saline: 3 mg/mL
SynonymsCismaplat; Cisplatina; cisplatinous diamine dichloride; cisplatinum; cisplatinum II; cisplatinum II diamine dichloride; CDDP; DDP; cisDDP; cisdiamminedichloro platinum (II); cisdiamminedichloroplatinum; Cisdichloroammine Platinum (II); CPDD; Cysplatyna; DDP; PDD; Peyrones Chloride; Peyrones Salt; CACP; Platinoxan; platinum diamminodichloride.

Trade names (US): Platinol; PlatinolAQ.

Trade names (other countries): Abiplatin; Blastolem; Briplatin; Cisplatyl; Citoplatino; Citosin; Lederplatin; Metaplatin; Neoplatin; Placis; Platamine; Platiblastin; PlatiblastinS; Platinex; Platinol AQ; PlatinolAQ VHA Plus; Platiran; Platistin; Platosin.

Chemical Name: (SP-4-2)-diamminedichloroplatinum; platinum, diaminedichloro-, cis-

SMILES CodeCl[Pt-2]([NH3+])([NH3+])Cl
实验参考方法
In Vitro

In vitro activity: Cisplatin, an inorganic platinum complex, is a chemotherapeutic agent and a potent inducer of growth arrest and apoptosis in a variety of cell types. It is used for the treatment a number of cancers including testicular cancer, ovarian cancer, cervical cancer, breast cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. Upon IV (intravenous) administration, Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. This inhibits DNA synthesis and results in apoptosis and cell growth inhibition. Cisplatin induces cytotoxic by interaction with DNA to form DNA adducts which activate several signal transduction pathways, including Erk, p53, p73, and MAPK, which culminates in the activation of apoptosis. Cisplatin (30 mM) treated for 6 h induces an apparent activation of Erk in HeLa cells, which is sustained over the following 14 h period. Cisplatin also shows an effective antineoplastic activity by inducing tumor cells death. Cisplatin displays ability to cause renal proximal tubular cell (RPTC) apoptosis, causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively. Cisplatin (800 μM) causes typical features of necrosis of RPTC after treatment for 4 hr.


Cell Assay: L1210/0 cells are maintained in an exponential suspension culture at 37 ℃ in a humidified atmosphere of 5% CO2 in McCoy's medium 5a (modified), supplemented with 15% calfserum, and Fungizone. L1210/0 cells are incubated in Cisplatin (7 μg/mL) for 2 hr at 37 ℃. To measure growth inhibition, the cells are centrifuged, washed once, resuspended in fresh medium at 30 × 103 to 50 × 103 cells/mL, and incubated for 3 days. Cell numbers are determined on a Coulter Counter. An aliquot of cells is diluted with an equal volume of 0.4% trypan blue. Viability is recorded as the percentage of cells that has excluded trypan blue. Cells incubated with Cisplatin as above are also diluted into 0.1% agar and allowed to grow for 2 weeks when colonies are counted.

In VivoCisplatin has been demonstrated to be efficient in regression tumor growth in a wide variety of animal tumors models, including head and neck cancer xenografts, cervical squamous carcinoma xenografts, testicular carcinoma xenografts, ovarian cancer xenografts, breast carcinoma xenografts, colonic carcinoma, heterotransplanted hepatoblastoma, and so on. Cisplatin (5 mg/kg) given weekly i.v. at the day 1 and 7 induces a tumor growth inhibition (GI) of 77.5% and 85.1% of the serous xenografts Ov.Ri(C) and OVCAR-3, respectively.
Animal modelThe human ovarian cancer xenografts OVCAR-3 in nude mice
Formulation & DosageDissolved in 0.9% NaCl solution; 5 mg/kg; i.v. injection
ReferencesOncogene. 2003 Oct 20;22(47):7265-79; Int J Cancer. 1992 Apr 22;51(1):108-15.
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024